Insilico has a connected set of capabilities for adapting AI to scientific work. MMAI Gym develops specialized models; benchmarking helps researchers assess their performance; Generative Biologics, ...
• Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, ...
The convergence of frontier artificial intelligence, large-scale biological data, and pharmaceutical innovation is opening new possibilities for understanding human aging, predicting disease, and ...
As autonomous AI agents evolve from conversational assistants into true scientific collaborators, the pharmaceutical industry is entering the next chapter of its AI transformation, one in which ...
Preclinical evaluation showed that ISM1354 possesses outstanding and highly consistent pharmacokinetic characteristics across multiple species, including mice, rats, dogs, and monkeys, achieving oral ...
FDA Fast Track- and Orphan Drug-designated program reflects Insilico’s strategy to advance AI-designed medicines against difficult-to-treat, age-associated diseases CAMBRIDGE, Mass. — September 22, ...
该项目已获 FDA 快速通道认定（Fast Track）和孤儿药（Orphan Drug）资格认定，体现了英矽智能推进 AI 设计药物应对难治性、衰老相关疾病的战略 马萨诸塞州剑桥，2026 年 9 月 23 日 — 由生成式人工 ...
在10月1日至3日于哈佛大学戴维·鲁宾斯坦树屋（David Rubenstein Treehouse）举行的第13届衰老研究与药物开发大会（ARDD）上，来自生物技术、全球制药公司、学术界和投资界的领袖齐聚一堂，共同 ...
随着自主 AI 智能体由“对话式助手”跃升为真正的“科学协作伙伴”，制药行业正跨入 AI 深度变革的新阶段 —— 药物发现全流程已从“AI 辅助”跨越至“AI 深度编排”的新格局。为推动“医药 ...
A retrosynthesis planner can only propose transformations that exist in its rule library. In template-based engines, those rules are generalized transforms that record the bonds that break or form, ...
在人口老龄化加速、肥胖及相关代谢疾病治疗需求持续攀升的背景下，GLP-1受体激动剂（GLP-1RA）类药物正迎来爆发式增长，其中替尔泊肽以2025年度365.07亿美元的销售额，问鼎全球新“药王 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results